Surgery Following Immune Checkpoint Inhibitions for Controlled Disease in Recurrent or Metastatic dMMR/MSI-H Colorectal Cancer

Sun Yat-sen University

Status: Completed

Conditions: Colorectal Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT06717763

B2020-064-Y01

Details and patient eligibility

About

Surgical resection for residual lesions could significantly improve the prognosis in metastatic colorectal cancers (CRCs) after systemic treatments, yet the necessity of resecting residual lesions after immune checkpoint inhibitions (ICIs) remains controversial in mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) diseases. We retrospectively enrolled recurrent or metastatic dMMR/MSI-H CRCs who received surgerys from Sun Yat-sen University Cancer Center. Patients without disease progression after at least 2 cycles of ICIs were included. Demographic and clinicopathological data were collected and analyzed. Relapse-free survival (RFS) after surgery were analyzed.

Enrollment: 40 patients

Sex: All

Ages: 16 to 74 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. pathologically confirmed CRC with measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1)20;
2. definite pathological or radiological evidence of recurrent or distant metastasis;
3. received at least 2 courses of ICIs;
4. confirmed as dMMR by immunohistochemical method or MSI-H by polymerase chain reaction or next-generation sequencing;
5. receiving therapeutic surgical treatment for residual lesions or tumor sites and achieving no evidence of disease (NED) ;
6. no progression within the duration of preoperative ICIs

Exclusion criteria